# Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer

> **NCT01048320** · PHASE1 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 36 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT01048320
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2012-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01048320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01048320, "Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01048320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*